2025 Market Insights: The Transformation of Polycythemia Vera Care

added blog Other

2025-11-09 11:26:41 -

The polycythemia vera treatment market is at a turning point as older therapies near patent expiry and new biologics enter the scene. JAKAFI (ruxolitinib) has been the standard of care for patients who are resistant or intolerant to hydroxyurea, but its anticipated generic competition may face delays. This postponement prolongs JAKAFI’s market dominance and keeps treatment costs high for...

0 Comments 0 Shares 596 Views 0 Reviews